
Results
17
Companies which are more than 50% undervalued based on analyst price target.
17 companies
Nanobiotix
Market Cap: €1.6b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€31.28
7D
-10.5%
1Y
616.6%
Inventiva
Market Cap: €912.0m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.86
7D
3.1%
1Y
41.7%
DBV Technologies
Market Cap: €735.6m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.49
7D
-11.6%
1Y
52.1%
Valneva
Market Cap: €403.9m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.13
7D
-6.2%
1Y
-20.2%
Cellectis
Market Cap: €166.7m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.30
7D
-9.7%
1Y
50.9%
Innate Pharma
Market Cap: €140.9m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.50
7D
-6.4%
1Y
-8.5%
Sensorion
Market Cap: €127.4m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.25
7D
-4.8%
1Y
-20.7%
OSE Immunotherapeutics
Market Cap: €74.1m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.15
7D
-4.4%
1Y
-39.0%
Adocia
Market Cap: €73.4m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.75
7D
0.3%
1Y
-14.1%
ABIONYX Pharma
Market Cap: €65.0m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.84
7D
-1.5%
1Y
46.9%
THX Pharma Société Anonyme
Market Cap: €51.2m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.71
7D
-6.2%
1Y
246.7%
MaaT Pharma
Market Cap: €49.4m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.62
7D
-2.1%
1Y
-39.6%
AB Science
Market Cap: €45.1m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.56
7D
-18.6%
1Y
-53.8%
Nicox
Market Cap: €32.6m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.37
7D
-6.3%
1Y
16.0%
Advicenne
Market Cap: €20.8m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.43
7D
-23.1%
1Y
11.2%
GenSight Biologics
Market Cap: €19.2m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
-0.2%
1Y
-37.2%
Valbiotis
Market Cap: €18.3m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.77
7D
-2.6%
1Y
-11.3%